Update on the Management of Kawasaki Disease

Kevin G. Friedman; Pei Ni Jone

doi:10.1016/j.pcl.2020.06.002

Update on the Management of Kawasaki Disease

Kevin G. Friedman^*, Pei Ni Jone

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%. However, patients with IVIG resistance, young infants, men, highly inflamed patients, and/or those with coronary changes at diagnosis remain at high risk for CAA. High-risk patients may benefit from acute, adjunctive antiinflammatory treatment in addition to IVIG. Optimal therapy remains unknown. This article reviews the acute pharmacologic management of patients with KD, focusing on adjunctive primary therapy options and treatment of patients with IVIG resistance.

Original language	English (US)
Pages (from-to)	811-819
Number of pages	9
Journal	Pediatric Clinics of North America
Volume	67
Issue number	5
DOIs	https://doi.org/10.1016/j.pcl.2020.06.002
State	Published - Oct 2020

Keywords

Coronary artery aneurysms
Corticosteroids
Intravenous immunoglobulin
Kawasaki disease

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.pcl.2020.06.002

Cite this

@article{aabc6c6d2c02401db10b705eaf60364c,

title = "Update on the Management of Kawasaki Disease",

abstract = "Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%. However, patients with IVIG resistance, young infants, men, highly inflamed patients, and/or those with coronary changes at diagnosis remain at high risk for CAA. High-risk patients may benefit from acute, adjunctive antiinflammatory treatment in addition to IVIG. Optimal therapy remains unknown. This article reviews the acute pharmacologic management of patients with KD, focusing on adjunctive primary therapy options and treatment of patients with IVIG resistance.",

keywords = "Coronary artery aneurysms, Corticosteroids, Intravenous immunoglobulin, Kawasaki disease",

author = "Friedman, {Kevin G.} and Jone, {Pei Ni}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

doi = "10.1016/j.pcl.2020.06.002",

language = "English (US)",

volume = "67",

pages = "811--819",

journal = "Pediatric Clinics of North America",

issn = "0031-3955",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Update on the Management of Kawasaki Disease

AU - Friedman, Kevin G.

AU - Jone, Pei Ni

PY - 2020/10

Y1 - 2020/10

N2 - Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%. However, patients with IVIG resistance, young infants, men, highly inflamed patients, and/or those with coronary changes at diagnosis remain at high risk for CAA. High-risk patients may benefit from acute, adjunctive antiinflammatory treatment in addition to IVIG. Optimal therapy remains unknown. This article reviews the acute pharmacologic management of patients with KD, focusing on adjunctive primary therapy options and treatment of patients with IVIG resistance.

AB - Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%. However, patients with IVIG resistance, young infants, men, highly inflamed patients, and/or those with coronary changes at diagnosis remain at high risk for CAA. High-risk patients may benefit from acute, adjunctive antiinflammatory treatment in addition to IVIG. Optimal therapy remains unknown. This article reviews the acute pharmacologic management of patients with KD, focusing on adjunctive primary therapy options and treatment of patients with IVIG resistance.

KW - Coronary artery aneurysms

KW - Corticosteroids

KW - Intravenous immunoglobulin

KW - Kawasaki disease

UR - http://www.scopus.com/inward/record.url?scp=85089295105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089295105&partnerID=8YFLogxK

U2 - 10.1016/j.pcl.2020.06.002

DO - 10.1016/j.pcl.2020.06.002

M3 - Review article

C2 - 32888683

AN - SCOPUS:85089295105

SN - 0031-3955

VL - 67

SP - 811

EP - 819

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

IS - 5

ER -

Update on the Management of Kawasaki Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this